- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Palladio begins ALERT Study for kidney disease treatment

During the study, ADPKD patients will receive lixivaptan for up to 58 weeks. Credit: John Campbell.